GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

18 Dec 2014
Price Change (% chg)

31.50p (+2.34%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for GSK.L


GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in... (more)


Beta: 0.55
Market Cap (Mil.): £65,509.10
Shares Outstanding (Mil.): 4,863.33
Dividend: 19.00
Yield (%): 5.94


  GSK.L Industry Sector
P/E (TTM): 15.70 36.60 37.24
EPS (TTM): 0.86 -- --
ROI: 16.65 18.95 18.21
ROE: 75.96 19.73 19.11
Search Stocks

UPDATE 1-New GSK shingles vaccine may challenge Merck after strong test data

* GSK vaccine cuts risk of shingles by 97.2 pct in over 50s

11:00am EST

GSK shareholders approve asset swap deal with Novartis

LONDON, Dec 18 - Shareholders in British drugmaker GlaxoSmithKline have approved a planned deal with Switzerland's Novartis, which will see the two pharmaceutical groups trade more than $20 billion of assets.

8:11am EST

GlaxoSmithKline shingles vaccine hits goal in major study

LONDON, Dec 18 - An experimental vaccine against shingles from GlaxoSmithKline met its goal in a late-stage study, in a boost for the company's vaccine unit, which is expanding part of its overall healthcare business.

7:42am EST

Fitch Affirms GlaxoSmithKline PLC at 'A+'; Revises Outlook to Negative

(The following statement was released by the rating agency) LONDON, December 17 (Fitch) Fitch Ratings has affirmed UK-based pharmaceuticals company GlaxoSmithKline PLC's (GSK) Long-term Issuer Default Rating (IDR) and senior unsecured rating at 'A+'. The Outlook has been revised to Negative from Stable. Fitch has also affirmed the senior unsecured rating of 'A+' for the debt issued under GlaxoSmithKline Capital PLC. The Negative Outlook encapsulates Fitch's expectation of increasing financia

17 Dec 2014

Antibiotic developer Cempra's CEO says not looking for a buyer

- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers.

12 Dec 2014

BRIEF-GSK files regulatory submission for variation to marketing authorisation for Ambrisentan

* GSK press release: GSK announces EU regulatory submission seeking extended indication for Ambrisentan (Volibris) in pulmonary arterial hypertension

11 Dec 2014

One shot or two? Many questions unresolved in Ebola vaccine race

* Debate over "prime-boost" vaccination as epidemic evolves

11 Dec 2014

BRIEF-Aspen Pharmacare director Abbas Hussain resigns

* Abbas Hussain has confirmed that he intends to tender his resignation as a director of company with effect from Feb. 1 2015

10 Dec 2014

Merck to take on superbugs with Cubist Pharma buy

- Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.

08 Dec 2014

UPDATE 4-Merck to take on superbugs with Cubist Pharma buy

* Merck to pay $8.4 bln, plus assumption of $1.1 bln of debt

08 Dec 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
Provider: Thomson Reuters Stock Report
Provider: GlobalData
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks